Full-Time

Field Medical Specialist Diabetes

Confirmed live in the last 24 hours

Dexcom

Dexcom

5,001-10,000 employees

Develops continuous glucose monitoring systems

No salary listed

Senior

Company Does Not Provide H1B Sponsorship

Remote in Spain

Travel required up to 80% mainly in Spain.

Category
Nursing & Allied Health Professionals
Medical, Clinical & Veterinary
Required Skills
Sales
Marketing
Requirements
  • Qualified Doctor, Dietitian, Nurse (or another relevant clinical qualification)
  • At least 5 years of experience in the education and treatment of patients with diabetes, with good knowledge of CGM and its use as a diabetes management tool
  • Excellent written and verbal communication skills required (for both patient and HCP communication)
  • A team-focused and collaborative approach to work
  • Fluent in English and Spanish, with the ability to read and interpret clinical and scientific documents, safety rules, operating and maintenance instructions, and procedure manuals
  • Flexibility to travel extensively across Spain (c.70-80% of the time)
Responsibilities
  • Facilitate and play a leadership role in the promotion of emerging clinical trial data, expanded indications, strategic publications, and health outcome research with KOLs and other relevant parties via presentations, discussions and face-to-face meetings, and publications
  • Provide medical and educational leadership and support to Commercial teams, including Marketing, Sales and Technical Support, in selected Direct Markets, and if requested also to selected distributors’ teams in Spain
  • Develop educational tools and clinical messaging needed for a variety of audiences - patient, Diabetes Nurse/ Dietitian and Educators, Physician and others
  • Collaborate with the EMEA and EMEA Marketing Departments, Research and Development, Regulatory, Clinical, Compliance and Quality, Customer Support and Field Sales and Clinical and Industry Partners
  • Collaborate with clinical colleagues worldwide in writing and presenting papers to diabetes journals

Dexcom develops and sells continuous glucose monitoring (CGM) systems designed to help individuals manage diabetes. The main product, the Dexcom G6 CGM System, provides users with real-time glucose readings, enabling better control of their condition. The system includes a sensor that is placed under the skin, which continuously measures glucose levels and sends the data to a smartphone or receiver. This allows users to monitor their glucose levels throughout the day without the need for fingerstick tests. Dexcom differentiates itself from competitors by offering a user-friendly interface and advanced data analytics through its Dexcom CLARITY software, which helps users and healthcare providers make informed decisions based on glucose trends. The goal of Dexcom is to enhance the quality of life for people with diabetes by providing accurate and accessible glucose monitoring solutions.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1999

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA clearance of G7 system enhances Dexcom's market credibility.
  • Integration with telehealth services boosts patient engagement and adherence.
  • AI integration in CGM systems improves predictive analytics and patient outcomes.

What critics are saying

  • Competition from Abbott's FreeStyle Libre 3 may impact market share.
  • Data privacy concerns with third-party platform integrations could deter users.
  • Hiring 1000 skilled workers may strain resources and cause inefficiencies.

What makes Dexcom unique

  • Dexcom G7 offers a 15-day wear period, reducing sensor replacements.
  • Direct Apple Watch connectivity allows glucose monitoring without an iPhone.
  • Dexcom CLARITY app provides detailed glucose patterns and trends analysis.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Remote Work Options

Flexible Work Hours

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Our Health Needs
Apr 14th, 2025
Dexcom receives FDA clearance for G7 15 Day glucose monitoring system

In March, cardiometabolic digital diagnostics company Nanowear announced a licensing and data partnership with Dexcom to integrate glucose data from the Dexcom G7 into its SimpleSense nanotechnology-enabled wearable.

Hit Consultant
Apr 10th, 2025
Fda Clears Dexcom G7 15 Day Continuous Glucose Monitoring System

What You Should Know:– Dexcom, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for individuals over the age of 18 with diabetes.– The Dexcom G7 15 Day system boasts an overall Mean Absolute Relative Difference (MARD) of 8.0% and builds upon the proven performance of Dexcom CGM technology, which has been clinically demonstrated to lower A1C, reduce hyper- and hypoglycemia, and increase time in range.Dexcom G7 FeaturesThe Dexcom G7 15 Day system offers up to 15.5 days of wear allowing users to benefit from fewer monthly sensors and reduced monthly waste. The waterproof CGM system provides an overall MARD of 8.0%.Other key features of Dexcom G7 include:Apple Watch Connectivity: Direct sensor connection to Apple Watch, allowing users to view glucose numbers without their iPhone.Direct sensor connection to Apple Watch, allowing users to view glucose numbers without their iPhone. Automated Logging: Automated activity logging, simplified meal logging, and new medication logging to help users understand the impact of these factors on glucose levels.Automated activity logging, simplified meal logging, and new medication logging to help users understand the impact of these factors on glucose levels. 12-Hour Grace Period: A 12-hour grace period for sensor replacement, ensuring a smoother transition between sessions.A 12-hour grace period for sensor replacement, ensuring a smoother transition between sessions. Mobile App with Dexcom Clarity: An innovative and user-friendly mobile app with Dexcom Clarity integration for easy viewing of glucose patterns, trends, and statistics through interactive reports.An innovative and user-friendly mobile app with Dexcom Clarity integration for easy viewing of glucose patterns, trends, and statistics through interactive reports

wflqzhanghaoran
Mar 27th, 2025
Dexcom COO on 15-day glucose sensor, Type 2 coverage | MedTech Dive

Dexcom is preparing to launch a 15-day version of its G7 continuous glucose monitor, based on data presented Thursday at the Advanced Technologies & Treatments for Diabetes conference.

MPO Magazine
Mar 26th, 2025
Dexcom Names Masimo Exec Jon Coleman as CCO

Dexcom names Masimo exec Jon Coleman as CCO.

Galway Beo
Mar 22nd, 2025
Dexcom opening date hiring 1000 jobs as highly skilled workers wanted

Dexcom opening date hiring 1000 jobs as highly skilled workers wanted.